Skip to content

Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis patients: A Multicenter Randomized Controlled Trial

Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis patients: A Multicenter Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230217001
Enrollment
96
Registered
2023-02-17
Start date
2021-09-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Change of cfPWV and progression of arterial stiffness after 12 and 24 weeks of oral MK-7 supplementation, Change of biochemistry parameters, vascular and bone turnover markers in blood after 12 and 24 weeks of oral MK-7 treatment, Incidence of side effects, thrombotic events and death from MK-7 supplement Menaquinone-7, Arterial stiffness, Carotid-femoral pulse wave velocity, Chronic hemodialysis

Interventions

Oral menaquinone-7 supplementation 375 microgram per day for duration of 24 week-study,Standard care with regular hemodialysis 2-3 times/week, adjusted by patients&#039
nephrologist.
Active Comparator Drug,No Intervention No treatment
Menaquinone-7 group,Control group

Sponsors

Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age equal or more than 18 years at screening Undergoing maintenance HD at least 2 times a week for more than 1 month prior to screening and compliance with HD treatments cfPWV measurement equal or more than 10 m/s at screening visit

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding Receiving vitamin K antagonist or warfarin Receiving and/or history of vitamin K supplementation in 3 months before screening History of percutaneous coronary intervention and/or coronary artery bypass grafting Patients with conditions that were unable to assess cfPWV including deformity of peripheral limbs, amputation, and severe peripheral vascular disease.

Design outcomes

Primary

MeasureTime frame
cPWV change 24 weeks Carotid-femoral pulse wave velocity

Secondary

MeasureTime frame
Change in blood sugar, HbA1C 24 weeks laboratory chemistry,Change in cholesterol 24 weeks laboratory chemistry,Change in iPTH, vitamin D (25-OH vitamin D) 24 weeks laboratory chemistry,Change in serum calcium, phosphate and albumin 24 weeks laboratory chemistry,Aortic calcification score 24 weeks abdominal lateral x-ray

Countries

Thailand

Contacts

Public ContactNuanjanthip Naiyarakseree

Faculty of Medicine, Chulalongkorn University

meannjt@gmail.com0840819040

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026